Novartis Gains Hepatitis Market Access Through Idenix Majority Stake
Executive Summary
Novartis is adding three novel hepatitis products to its antiviral pipeline through a 51% stake in the privately held biotech company Idenix
You may also be interested in...
Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says
Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15
Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says
Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15
Biotech Startups Trading IPO Filings For Selling Block – BIO Panel
The goal of a biotech startup appears to have shifted away from a focus on entering the public market through an IPO in favor of building the company to become an acquisition target